NCT06566638View on ClinicalTrials.gov

Safety, Tolerability and Performance of the NucleoCapture Extracorporeal Therapeutic Apheresis Device in the Reduction of Circulating cfDNA/NETs in Subjects With Pancreatitis

NANot yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

December 5, 2026

Study Completion Date

April 1, 2027

Conditions
Acute PancreatitisOrgan Failure, Multiple
Interventions
DEVICE

NucleoCapture device

100ml NucleoCapture selective DNA adsorber.

Trial Locations (1)

Unknown

Liverpool University Hospitals NHS Foundation Trust, Liverpool

All Listed Sponsors
collaborator

Santersus AG

INDUSTRY

lead

Liverpool University Hospitals NHS Foundation Trust

OTHER_GOV

NCT06566638 - Safety, Tolerability and Performance of the NucleoCapture Extracorporeal Therapeutic Apheresis Device in the Reduction of Circulating cfDNA/NETs in Subjects With Pancreatitis | Biotech Hunter | Biotech Hunter